KR20220082934A - 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 - Google Patents

지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 Download PDF

Info

Publication number
KR20220082934A
KR20220082934A KR1020227018854A KR20227018854A KR20220082934A KR 20220082934 A KR20220082934 A KR 20220082934A KR 1020227018854 A KR1020227018854 A KR 1020227018854A KR 20227018854 A KR20227018854 A KR 20227018854A KR 20220082934 A KR20220082934 A KR 20220082934A
Authority
KR
South Korea
Prior art keywords
implant
eye
biodegradable
months
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018854A
Other languages
English (en)
Korean (ko)
Inventor
제인-구오 시아
라훌 바가트
웬디 엠. 블랜다
티에리 니바지올리
린 펭
데이비드 초우
데이비드 에이. 웨버
Original Assignee
알레간 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220082934(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알레간 인코포레이티드 filed Critical 알레간 인코포레이티드
Priority to KR1020247013455A priority Critical patent/KR20240058976A/ko
Publication of KR20220082934A publication Critical patent/KR20220082934A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020227018854A 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 Ceased KR20220082934A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247013455A KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
KR1020167015466A KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015466A Division KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013455A Division KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Publications (1)

Publication Number Publication Date
KR20220082934A true KR20220082934A (ko) 2022-06-17

Family

ID=52001114

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247013455A Ceased KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020227018854A Ceased KR20220082934A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020167015466A Active KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247013455A Ceased KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167015466A Active KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Country Status (24)

Country Link
US (2) US20150140062A1 (enExample)
EP (2) EP3068403B2 (enExample)
JP (2) JP6675307B2 (enExample)
KR (3) KR20240058976A (enExample)
CN (1) CN105764517A (enExample)
AU (4) AU2014348369B2 (enExample)
CA (1) CA2929689A1 (enExample)
CL (1) CL2016001167A1 (enExample)
CY (1) CY1123344T1 (enExample)
DK (1) DK3068403T3 (enExample)
ES (1) ES2819215T3 (enExample)
HU (1) HUE050913T2 (enExample)
IL (2) IL245548A0 (enExample)
MX (2) MX2016006334A (enExample)
MY (1) MY176039A (enExample)
NZ (1) NZ719953A (enExample)
PH (1) PH12016500869B1 (enExample)
PL (1) PL3068403T3 (enExample)
PT (1) PT3068403T (enExample)
RU (1) RU2690841C1 (enExample)
SG (1) SG10201809363SA (enExample)
SI (1) SI3068403T1 (enExample)
UA (1) UA122117C2 (enExample)
WO (1) WO2015073895A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6914931B2 (ja) * 2015-07-23 2021-08-04 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
KR20230041708A (ko) * 2020-07-16 2023-03-24 오큘라 테라퓨틱스, 인코포레이티드 글루코코르티코이드를 함유하는 안구 삽입물
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
WO2012109673A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Also Published As

Publication number Publication date
UA122117C2 (uk) 2020-09-25
US20250319031A1 (en) 2025-10-16
CL2016001167A1 (es) 2017-01-06
IL245548A0 (en) 2016-06-30
NZ719953A (en) 2022-01-28
SG10201809363SA (en) 2018-11-29
MX2016006334A (es) 2016-09-06
KR20240058976A (ko) 2024-05-07
AU2022204607A1 (en) 2022-07-21
PT3068403T (pt) 2020-09-18
CA2929689A1 (en) 2015-05-21
US20150140062A1 (en) 2015-05-21
CN105764517A (zh) 2016-07-13
KR20160085847A (ko) 2016-07-18
ES2819215T3 (es) 2021-04-15
PH12016500869A1 (en) 2016-07-04
JP7022735B2 (ja) 2022-02-18
MY176039A (en) 2020-07-22
CY1123344T1 (el) 2021-12-31
PL3068403T3 (pl) 2021-01-11
AU2024205640B2 (en) 2025-10-23
RU2016119132A (ru) 2017-12-20
HUE050913T2 (hu) 2021-01-28
SI3068403T1 (sl) 2020-11-30
AU2020204362A1 (en) 2020-07-23
AU2024205640A1 (en) 2024-08-29
EP3068403B1 (en) 2020-06-17
DK3068403T3 (da) 2020-09-07
RU2690841C1 (ru) 2019-06-06
EP3068403A1 (en) 2016-09-21
IL290837A (en) 2022-04-01
AU2014348369A1 (en) 2016-06-09
KR102475746B1 (ko) 2022-12-08
WO2015073895A1 (en) 2015-05-21
EP3714875A1 (en) 2020-09-30
MX2022002306A (es) 2022-03-25
PH12016500869B1 (en) 2016-07-04
AU2014348369B2 (en) 2020-04-02
JP6675307B2 (ja) 2020-04-01
JP2020055862A (ja) 2020-04-09
EP3068403B2 (en) 2025-12-03
JP2016538292A (ja) 2016-12-08

Similar Documents

Publication Publication Date Title
AU2024205640B2 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
US20230172948A1 (en) Ocular implant made by a double extrusion proces
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
Bansal et al. Posterior segment drug delivery devices: current and novel therapies in development
Holló Wound healing and glaucoma surgery: modulating the scarring process with conventional antimetabolites and new molecules
Lee et al. Novel drug delivery systems for retinal diseases: a review
US20150272877A1 (en) Ketorolac-containing sustained release drug delivery systems
RU2015144119A (ru) Ускоренное заживление повреждений глаз с помощью ангиотензиновых пептидов
de Oliveira Dias et al. New drugs and new posterior delivery methods in CME
HK40038783A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770B (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration
HK1183436A (en) Intraocular pressure reduction with intracameral bimatoprost implants

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220603

Application number text: 1020167015466

Filing date: 20160610

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220701

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220726

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220726

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230516

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230126

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20231123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231016

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230516

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230126

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220726

X601 Decision of rejection after re-examination